Taysha Gene Therapies, Inc.

Taysha Gene Therapies, Inc. (TSHA) priced its initial public offering on Sep 25, 2020 at $20.00 per share, raising $157.4M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $716.2M. Goldman Sachs was lead-left underwriter, joined by Morgan Stanley, Jefferies and Chardan. Cooley advised the company and Goodwin Procter advised the underwriters.

Taysha Gene Therapies, Inc. is a gene therapy company developing AAV-based treatments for monogenic diseases of the central nervous system. Founded in partnership with UT Southwestern Medical Center, it is advancing 18 gene therapy product candidates and holds options on four more programs.

Status

IPO

Ticker

TSHA

Exchange

Nasdaq Global Select

Priced

Sep 25, 2020

IPO price

$20.00

Raised

$157.4M

Market cap at IPO price

$716.2M

First filed

Sep 2, 2020

Underwriters

Goldman Sachs, Morgan Stanley, Jefferies and Chardan

Company counsel

Cooley

Underwriters' counsel

Goodwin Procter

Sector

Biotech & pharma

Country / state

TX

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.